Results 171 to 180 of about 4,770 (180)

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

New England Journal of Medicine, 2019
Peter Gordon Middleton, Marcus A Mall, Larry C Lands   +2 more
exaly  

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

New England Journal of Medicine, 2017
Felix C C Ringshausen, John Wilson, Elizabeth Tullis   +2 more
exaly  

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine, 2018
Lucy Burr, Marcus A Mall, Edward F Mckone   +2 more
exaly  

Elexacaftor/Ivacaftor/tezacaftor/Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Ivacaftor/tezacaftor

Reactions Weekly
openaire   +1 more source

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2020
openaire   +2 more sources

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Edward McKone, Marcus Mall
exaly  

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Lancet Respiratory Medicine,the
exaly  

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Lancet Respiratory Medicine,the
exaly  

Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis

Lancet, The
exaly